Dermatologic infections in cancer patients treated with checkpoint inhibitors-Reference-Cited by-同舟云学术

Dermatologic infections in cancer patients treated with checkpoint inhibitors

Published:2021-12 Issue:6 Volume:85 Page:1528-1536
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Do Mytrang H.,Barrios Dulce M.,Phillips Gregory S.,Postow Michael A.,Warner Allison Betof,Rosenberg Jonathan E.,Noor Sarah J.,Markova Alina,Lacouture Mario E.

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Dermatology Foundation

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Dermatology

Reference42 articles.

1. Fundamental mechanisms of immune checkpoint blockade therapy;Wei;Cancer Discov,2018

2. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015

3. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

5. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis;Minkis;J Am Acad Dermatol,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cemiplimab/ipilimumab/nivolumab;Reactions Weekly;2022-01

2. European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement;Journal of the European Academy of Dermatology and Venereology;2021-12-15

3. Antimicrobial immunotherapeutics: past, present and future;Emerging Topics in Life Sciences;2021-07-01